tiprankstipranks
Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome
PremiumPress ReleasesQuoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome
5M ago
Quoin Pharmaceuticals announces FDA clearance for plan for QRX003 trials
PremiumThe Fly
Quoin Pharmaceuticals announces FDA clearance for plan for QRX003 trials
5M ago
Quoin Pharmaceuticals reports Q3 EPS ($1.95), consensus ($2.72)
PremiumThe Fly
Quoin Pharmaceuticals reports Q3 EPS ($1.95), consensus ($2.72)
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100